Literature DB >> 21031523

Prospective comparison of image quality and diagnostic accuracy of 0.5 molar gadobenate dimeglumine and 1.0 molar gadobutrol in contrast-enhanced run-off magnetic resonance angiography of the lower extremities.

Marina Achenbach1, Jens H Figiel, Mykhaylo Burbelko, Johannes T Heverhagen.   

Abstract

PURPOSE: To compare image quality and diagnostic accuracy of 0.5 molar gadobenate dimeglumine and 1.0 molar gadobutrol in contrast-enhanced (CE) magnetic resonance angiography (MRA) of the lower extremities interindividually.
MATERIALS AND METHODS: The study was approved by our Institutional Review Board. Written informed consent was obtained from all patients before enrollment in the study. We prospectively included 74 patients (21 women, 53 men; mean age ± SD: 67.9 ± 11.0 years) with suspected peripheral occlusive vascular disease. All patients underwent a contrast-enhanced MRA of both lower extremities with either 0.1 mL/kg body weight gadobutrol or gadobenate dimeglumine. Image quality, stenosis grade, and artifacts were assessed by two blinded, independent investigators. Signal intensity (SI), signal-to-noise ratio (SNR), and contrast-to-noise ratio (CNR) were measured by a third investigator. Contrast agent groups were compared to each other using a two-sided Student's t-test.
RESULTS: The results did not show significant differences for SI, SNR, or CNR. Both investigators were in significant accordance (P < 0.05) with regard to stenosis detection.
CONCLUSION: We conclude that application of standard clinical doses (0.1 mL/kg body weight) of both contrast agents provides similar diagnostic results and gadolinium dose could be reduced by the application of a single dose of gadobenate dimeglumine for CE run-off MRA.
© 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21031523     DOI: 10.1002/jmri.22355

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  9 in total

1.  Does higher gadolinium concentration play a role in the morphologic assessment of brain tumors? Results of a multicenter intraindividual crossover comparison of gadobutrol versus gadobenate dimeglumine (the MERIT Study).

Authors:  Z Seidl; J Vymazal; M Mechl; M Goyal; M Herman; C Colosimo; M Pasowicz; R Yeung; B Paraniak-Gieszczyk; B Yemen; N Anzalone; A Citterio; G Schneider; S Bastianello; J Ruscalleda
Journal:  AJNR Am J Neuroradiol       Date:  2012-03-01       Impact factor: 3.825

2.  Contrast-enhanced MR angiography: does a higher relaxivity MR contrast agent permit a reduction of the dose administered for routine vascular imaging applications?

Authors:  Xiaoying Xing; Xiangzhu Zeng; Xuan Li; Qiang Zhao; Miles A Kirchin; Gianpaolo Pirovano; Xiaoying Wang; Yuan Li; Roberto Iezzi; Francesco De Cobelli
Journal:  Radiol Med       Date:  2014-09-03       Impact factor: 3.469

3.  The Benefits of High Relaxivity for Brain Tumor Imaging: Results of a Multicenter Intraindividual Crossover Comparison of Gadobenate Dimeglumine with Gadoterate Meglumine (The BENEFIT Study).

Authors:  M Vaneckova; M Herman; M P Smith; M Mechl; K R Maravilla; J Weichet; M V Spampinato; J Žižka; F J Wippold; J J Baima; R Babbel; E Bültmann; R Y Huang; J-H Buhk; A Bonafé; C Colosimo; S Lui; M A Kirchin; N Shen; G Pirovano; A Spinazzi
Journal:  AJNR Am J Neuroradiol       Date:  2015-07-16       Impact factor: 3.825

4.  Multicenter, intraindividual comparison of single-dose gadobenate dimeglumine and double-dose gadopentetate dimeglumine for MR angiography of the supra-aortic arteries (the Supra-Aortic VALUE study).

Authors:  Yanjun Li; X Li; D Li; J Lu; X Xing; F Yan; Yuan Li; X Wang; R Iezzi; F De Cobelli
Journal:  AJNR Am J Neuroradiol       Date:  2012-10-04       Impact factor: 3.825

5.  Dynamic and static magnetic resonance angiography of the supra-aortic vessels at 3.0 T: intraindividual comparison of gadobutrol, gadobenate dimeglumine, and gadoterate meglumine at equimolar dose.

Authors:  Jens Harald Kramer; Elisabeth Arnoldi; Christopher J François; Andrew L Wentland; Konstantin Nikolaou; Bernd J Wintersperger; Thomas M Grist
Journal:  Invest Radiol       Date:  2013-03       Impact factor: 6.016

6.  Safety and adverse effects during 24 hours after contrast-enhanced MRI with gadobenate dimeglumine (MultiHance) in children.

Authors:  Guenther Schneider; Hellmut Schürholz; Miles A Kirchin; Arno Bücker; Peter Fries
Journal:  Pediatr Radiol       Date:  2012-11-24

7.  Gdn 3+@CNTs-PEG versus Gadovist®: In Vitro Assay.

Authors:  Ghazal Mehri-Kakavand; Hadi Hasanzadeh; Rouzbeh Jahanbakhsh; Maryam Abdollahi; Reza Nasr; Ahmad Bitarafan-Rajabi; Majid Jadidi; Amir Darbandi-Azar; Alireza Emadi
Journal:  Oman Med J       Date:  2019-03

8.  Enhancement characteristics and impact on image quality of two gadolinium chelates at equimolar doses for time-resolved 3-Tesla MR-angiography of the calf station.

Authors:  Jan Hansmann; Henrik J Michaely; John N Morelli; André Luckscheiter; Stefan O Schoenberg; Ulrike I Attenberger
Journal:  PLoS One       Date:  2014-06-03       Impact factor: 3.240

9.  Gadobutrol Precedes Gd-DTPA in Abdominal Contrast-Enhanced MRA and MRI: A Prospective, Multicenter, Intraindividual Study.

Authors:  Xijiao Liu; Zhengyan Li; Weiwei Zhang; Caiwei Yang; Yike Diao; Ting Duan; Yu Fu; Jing Ren; Song Bin
Journal:  Contrast Media Mol Imaging       Date:  2019-12-02       Impact factor: 3.161

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.